

FOR MANUFACTURER PARTNERS

# QuantifyRx

REMS-grade specialty network capabilities for high-cost, high-risk therapies.

Quantify Specialty Care (QSC) is a clinician-led specialty organization serving self-funded employer plans. QuantifyRx is its URAC-accredited pharmacy subsidiary — URAC Specialty Pharmacy Services accreditation in progress. Our operating model delivers REMS-grade oversight in the home: anaphylaxis-trained registered nurses, physician-overseen escalation, cellular-monitored cold chain, and a named clinical contact per patient.

Legal entity	UrgentMedRx, LLC doing business as QuantifyRx
URAC accreditation	MSP010001 (Mail-Service Pharmacy); Specialty Pharmacy Services accreditation in progress
Memberships	NHIA · NCPA
Operating address	4901 NW 17th Way, Suite 302, Fort Lauderdale, FL 33309
Manufacturer contact	Liane Parker, RN, CPHM — Co-Founder & COO liane@quantifysc.com · (888) 536-9963
Pharmacist of record	Carl Black, PharmD — Chief Pharmacy Officer, QuantifyRx
Medical oversight	Alberto Montero, MD — Chair, Quality Medical Oversight Committee

# REMS-Plus, not REMS-aspirational.

## **Anaphylaxis-readiness as a baseline**

For any therapy with an anaphylaxis or hypersensitivity risk, the operating standard is not negotiable: anaphylaxis-trained registered nurses physically in the home for every infusion, standardized epinephrine and emergency kits with audit-ready chain of custody, documented patient and caregiver pre-infusion education, real-time physician availability for hypersensitivity escalation, and post-event reporting back to the manufacturer within defined SLAs.

## **Named clinical contacts**

Every patient is assigned a named pharmacist and a named bedside RN. Both know the patient by name. Both know the prescribing physician by name. Both know the manufacturer's REMS protocol by heart. Communication routes through a single phone line — answered by a human, 24/7 — not a queue, not a portal, not a general-line interactive voice response system.

## **Physician oversight that is real**

Our Quality Medical Oversight Committee is a standing panel of board-certified physicians (oncology, cardiology, endocrinology, infectious disease, internal medicine) and senior clinical RNs that reviews complex cases, treatment protocols, prior-authorization decisions, and protocol appropriateness. The committee can — and does — change the treatment plan when a less invasive, equally effective, or clinically superior pathway exists for the patient in front of us.

## **Continuous physiologic monitoring**

Between doses, patients on high-risk therapies are monitored through QSC's 24/7 Virtual Command Center: connected vitals, symptom check-ins, medication-adherence tracking, and triage to clinician when something changes. Adverse events are detected hours and days earlier than the dispense-and-ship industry standard.

# A cold chain you can audit.

Cold-chain failure is the most common, the most expensive, and the most quietly tolerated form of waste in specialty pharmacy. Industry-wide temperature-excursion losses cost an estimated \$35 billion annually. Our model is built so the manufacturer can verify temperature integrity end-to-end, not take our word for it.

Specification	QuantifyRx standard
Temperature range	2–8°C maintained end-to-end, manufacturer warehouse to patient bedside
Hold duration	72+ hours hold time per shipment
Dry ice	Not required (reduces logistics burden, eliminates DOT hazmat overhead)
Monitoring	Cellular GPS + temperature + humidity sensors, transmitting in real time
Excursion detection	Auditable per-shipment record; deviation alerts route to pharmacist within minutes
Logistics partner	Cardinal Health distribution backbone with QuantifyRx-defined SLAs
Patient-side verification	Tamper-evident packaging; member confirms intact seal before nurse administers

Every shipment generates an audit packet available to the manufacturer on request. Excursions trigger automatic clinical hold, reorder, and root-cause review — not silent dispense.

## A formal, criteria-based evaluation.

We are requesting that the manufacturer evaluate Quantify Specialty Care and QuantifyRx for inclusion in REMS-certified or limited-distribution specialty networks for high-cost, high-risk therapies — using the same criteria applied to any candidate organization. We are not asking partners to lower the safety bar. We are asking to be measured fairly against it.

### What a formal review would include

#### Document review

URAC accreditation status (MSP010001), state pharmacy licensure, REMS workflow SOPs, anaphylaxis emergency-response protocols, cold-chain validation reports, and quality oversight committee charter.

#### On-site or virtual operational audit

Walkthrough of Fort Lauderdale dispensing operations, REMS workflow, cold-chain handling, and clinical command center.

#### Clinical case review

Anonymized review of complex specialty cases QSC currently manages, including the Quality Medical Oversight Committee's role in clinical appropriateness review.

#### Outcomes benchmarking

Anaphylaxis incidence, ER utilization, time-to-stable-dosing, adherence, and member-experience metrics measured against published incumbent benchmarks for therapies in the same class.

#### Defined pathway to network inclusion

A clear set of criteria, a defined timeline, and a named clinical lead at the manufacturer for escalations and review.

### Contact for evaluation

Liane Parker, RN, CPHM · Co-Founder & Chief Clinical Operating Officer  
liane@quantifysc.com · (888) 536-9963 · [quantifyrx.vercel.app](https://quantifyrx.vercel.app)